Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

Stock Information for Akari Therapeutics Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akari Therapeutics Plc

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Announces Pricing of Public Offering
Corbus Pharmaceuticals Announces Proposed Public Offering
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.